Tags

Type your tag names separated by a space and hit enter

Ranitidine versus cimetidine in the healing of erosive esophagitis.
Clin Ther. 1996 Nov-Dec; 18(6):1150-60.CT

Abstract

Ranitidine 150 mg twice daily (BID) is an approved therapeutic approach for relieving the symptoms of gastroesophageal reflux disease. Ranitidine 150 mg four times daily (QID) and cimetidine 800 mg BID are indicated for endoscopically diagnosed erosive esophagitis. This 12-week, randomized, multicenter trial involving 696 patients compared ranitidine 150 mg BID and ranitidine 150 mg QID with cimetidine 800 mg BID in healing erosive esophagitis. Healing rates, as determined by endoscopy, at 4, 8, and 12 weeks were comparable with ranitidine 150 mg BID (38%, 56%, and 71%, respectively) and cimetidine 800 mg BID (37%, 52%, and 68%, respectively), as were reductions in heartburn frequency and antacid consumption. However, ranitidine 150 mg QID produced significantly higher healing rates (49%, 67%, and 77%, respectively) and greater reductions in heartburn frequency and antacid consumption than cimetidine 800 mg BID. All treatment regimens were well tolerated. Thus ranitidine 150 mg BID is as effective as cimetidine 800 mg BID, and ranitidine 150 mg QID is more effective than cimetidine 800 mg BID in healing erosive esophagitis and reducing heartburn frequency and antacid consumption.

Authors+Show Affiliations

Glaxo Wellcome Inc., Research Triangle Park, North Carolina, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9001831

Citation

McCarty-Dawson, D, et al. "Ranitidine Versus Cimetidine in the Healing of Erosive Esophagitis." Clinical Therapeutics, vol. 18, no. 6, 1996, pp. 1150-60.
McCarty-Dawson D, Sue SO, Morrill B, et al. Ranitidine versus cimetidine in the healing of erosive esophagitis. Clin Ther. 1996;18(6):1150-60.
McCarty-Dawson, D., Sue, S. O., Morrill, B., & Murdock, R. H. (1996). Ranitidine versus cimetidine in the healing of erosive esophagitis. Clinical Therapeutics, 18(6), 1150-60.
McCarty-Dawson D, et al. Ranitidine Versus Cimetidine in the Healing of Erosive Esophagitis. Clin Ther. 1996 Nov-Dec;18(6):1150-60. PubMed PMID: 9001831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ranitidine versus cimetidine in the healing of erosive esophagitis. AU - McCarty-Dawson,D, AU - Sue,S O, AU - Morrill,B, AU - Murdock,R H,Jr PY - 1996/11/1/pubmed PY - 2001/3/28/medline PY - 1996/11/1/entrez SP - 1150 EP - 60 JF - Clinical therapeutics JO - Clin Ther VL - 18 IS - 6 N2 - Ranitidine 150 mg twice daily (BID) is an approved therapeutic approach for relieving the symptoms of gastroesophageal reflux disease. Ranitidine 150 mg four times daily (QID) and cimetidine 800 mg BID are indicated for endoscopically diagnosed erosive esophagitis. This 12-week, randomized, multicenter trial involving 696 patients compared ranitidine 150 mg BID and ranitidine 150 mg QID with cimetidine 800 mg BID in healing erosive esophagitis. Healing rates, as determined by endoscopy, at 4, 8, and 12 weeks were comparable with ranitidine 150 mg BID (38%, 56%, and 71%, respectively) and cimetidine 800 mg BID (37%, 52%, and 68%, respectively), as were reductions in heartburn frequency and antacid consumption. However, ranitidine 150 mg QID produced significantly higher healing rates (49%, 67%, and 77%, respectively) and greater reductions in heartburn frequency and antacid consumption than cimetidine 800 mg BID. All treatment regimens were well tolerated. Thus ranitidine 150 mg BID is as effective as cimetidine 800 mg BID, and ranitidine 150 mg QID is more effective than cimetidine 800 mg BID in healing erosive esophagitis and reducing heartburn frequency and antacid consumption. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/9001831/Ranitidine_versus_cimetidine_in_the_healing_of_erosive_esophagitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0149-2918(96)80069-5 DB - PRIME DP - Unbound Medicine ER -